• Immitra Bio

  Participated · Seed · Jul 2026

  Immitra Bio is developing scalable, one-time curative in-vivo gene editing therapies built around a mutation-agnostic editing approach and a digital target discovery platform. Its lead candidate, IB-003, is being developed as a potential one-time curative in-vivo gene editing treatment for an inherited anemia. The company's approach is designed to avoid complex ex-vivo cell manipulation, patient conditioning, and stem cell transplantation, aiming to enable off-the-shelf formulations that treat all patients within a given disease regardless of underlying mutation. Immitra Bio says its platform could generate dozens of differentiated therapeutic assets more quickly than highly personalized approaches. The recent CHF 2.4 million pre-seed financing will primarily fund preclinical proof-of-concept work for IB-003 and support additional discovery and validation across the pipeline and platform refinement. The company highlights scalability and commercial viability as core objectives for its technology.

• nsave

  Participated · Seed · Mar 2024

  nsave offers trusted dollar, sterling and euro accounts abroad to people from countries with high inflation, working with regulated financial institutions and banking partners in the UK and Switzerland. The company has launched an investment product that lets customers access US equities, ETFs and, soon, funds managed by major asset managers via the nsave app, subject to onboarding and compliance checks. nsave targets young professionals facing exclusionary compliance processes and people from high-inflation economies seeking to protect and grow their savings. The business emphasizes a compliance-by-design approach to enable services safely and more broadly. nsave is led by founders Amer Baroudi and Abdallah AbuHashem and is based in London and Geneva. The company recently completed a notable financing to accelerate growth. nsave is a Swiss fintech founded in 2022 by Amer Baroudi and Abdallah AbuHashem that helps people in countries with unstable banking sectors or high inflation open offshore accounts. Its product provides trusted accounts denominated in dollar, euro or pound through partnerships with regulated financial institutions. Users sign up on an app and complete an onboarding journey that includes risk assessment and dynamic, automated enhanced due diligence when required. The company uses a proprietary transaction‑monitoring tool to comply with Swiss anti‑money laundering and counter‑terrorist financing regulations. nsave is live but in the early stages of product development and plans to double down on the savings and wealth side of retail banking. The team is targeting millions of people in distressed economies, citing examples such as Lebanon where inflation and currency devaluation have eroded savings.

• HeroSupport

  Led · Debt Financing · Feb 2024

  HeroSupport is a Geneva University Hospital (HUG) spinoff developing medical devices that transform imaging and treatment tables into patient-specific supports so the table adapts to each patient. Its technology aims to make cancer treatment more precise and effective by improving patient comfort, reducing treatment duration and costs, and lowering side-effects through elimination of x-ray imaging. The company is led by founder and CEO Dr. Giovanna DiPasquale, a Medical Physicist at HUG. HeroSupport previously received a FIF Grant of CHF 50,000 in 2021 and has now been awarded further FIF funding to advance its technology. The recent award is a convertible FIF seed loan that will support continued development and scale-up within the FIF program. The product benefits and grant/loan awards position the company to progress clinical and commercial development in the near term. HeroSupport is a Geneva-based medtech startup that develops 3D-printed personalised patient-positioning immobilisation devices for prone breast radiotherapy. Its first product, VENUS SHELL, is an MRI-compatible custom breast shell created by 3D scanning the patient’s breast on the EYE-table and 3D printing a personalised shell that attaches to hospital treatment boards for precise, comfortable, and quick positioning. The company positions the device as improving treatment effectiveness, safety, and cost-efficiency and aims to increase use of prone positioning, which the article notes reduces skin burns and lowers lung and cardiac death risks. HeroSupport spun out of Geneva University Hospital, where the device was tested in a clinical trial, and was founded by CEO Giovanna Dipasquale and CTO Johan Uiterwijk. It received CHF 150,000 from Venture Kick and will use the funds to set up a 3D printing lab and complete certification to work with its first customers. The startup is currently raising its first financing round to accelerate international expansion and plans to target large radiotherapy centres in the EU, US, and Australia.

• Transmutex SA

  Participated · Series A · Jan 2024

  Transmutex develops a non-self-sustaining reaction technology that couples a particle accelerator to a subcritical fuel assembly. The system can be stopped in 2 milliseconds and is designed to use different fuel materials and enrichment levels, including thorium. Subcriticality offers a wider safety margin and enables more efficient burning of existing long‑lived nuclear waste; when thorium is used it will not produce plutonium and other long‑lived waste. Combined with innovative spent-fuel recycling technology, the company says the system can be made sustainable for energy production over centuries. Founded on 29 July 2019 and based in Geneva, Switzerland, Transmutex intends to use the new funds to further develop its solution. It raised over CHF 20M in an extension of its Series A. Transmutex is developing a breakthrough nuclear energy process technology that originated at CERN. The technology is designed to be intrinsically safe, reduce the stockpile of long-lived waste, resist military proliferation, and be cost-competitive. The company has partnered with leading research centres and industry players to advance development. Transmutex aims to deliver a pilot nuclear plant within a decade. The company is based in Geneva and positions its work in service of sustainability goals. Financially, Transmutex recently received a CHF 100,000 seed loan from the Fongit Innovation Fund (FIF). Transmutex develops accelerator-based nuclear technology to transmute long-lived radioactive waste into different elements, reducing the radioactivity of the most dangerous waste by a factor of 1,000. Its process uses particle accelerators and a thorium-fuel approach to both reduce waste and produce carbon-free energy that can be reinjected into the grid or used to produce green hydrogen. The company presents its design as a more secure reactor concept than existing ones and aims to enable scalable carbon-free energy without the traditional challenges of nuclear plants. The underlying technologies have been tested at CERN, and Transmutex has a collaboration agreement with the Paul Scherrer Institute (PSI) to access nuclear safety expertise, fuel-cycle analysis, spallation target design, and cyclotron operation. Transmutex was co-founded in 2019 in Geneva and has advanced R&D through external funding, including a CHF 2.6 million seed round closed in May 2020. The new CHF 5.3 million financing brings the company’s total equity capital to CHF 8 million since January 2020 and will be used to accelerate research and development activities.

• Resolve

  Led · Equity · Oct 2023

  Resolve SA operates a platform that connects private borrowers with financial institutions, offering services including mortgage financing, retirement planning and taxation. The company is registered with FINMA. Resolve employs about 50 people and is headquartered in Geneva with offices across Switzerland. The article notes Resolve received a CHF 100,000 growth loan (Prêt de Croissance) from the FONGIT Innovation Fund (FIF). The funding comes from a programme that supports the development of innovative companies in the Canton of Geneva. Resolve, founded in 2018 in Geneva by Florian Bienefelt and Yannis Eggert, offers a digital platform to make mortgage origination simpler, faster and more transparent while pairing that technology with adviser expertise. The company is focused on supporting advisers via its platform and continuing product investment. Resolve is in strong growth and plans to accelerate deployment across Switzerland. The recent transaction enabled employee participation in the cap table, with more than half of employees subscribing. Resolve expects to leverage the strategic investor’s brokerage experience and network to scale operations and distribution.

No current team members are available.